Between March 2021to and March 2023, 62 cases were evaluated. The median age was 74.5 (range 56-83) years, all patients were postmenopausal, 40 patients (64.5%) were diagnosed with POP-Q stage III, and 22 patients (35.5%) were diagnosed with POP-Q Stage IV. Preoperatively, two patients (3.2%) were diagnosed with sarcopenia. Median 6 m walking speed was significantly improved at one month (6.1, range: 4.0-10.2 sec) (p=0.045), three months (5.9, range: 4.1-10.4 sec) (p=0.003), six months (6.0, range: 4.1-10.2 sec) postoperatively compared with the baseline value (6.9, range: 4.2-11.5 sec), however, at 12 months (6.1, range: 4.1-10.0 sec) (p=0.082), no statistically significant improvement was observed compared to baseline value. Medan hand grip strength was also significantly improved at one month (20.0, range: 10.5-34.7 kg) (p=0.008), three months (20.3, range: 10.5-34.7 kg) (p<0.001) six months (20.1, range: 10.5-34.7 kg) postoperatively compared with the baseline value (19.1, range: 10.4-31.7 kg), but no statistically significant difference was observed at 12 months (19.6, range: 10.8-30.4 kg). Conversely, median ASM significantly decreased at one month (6.48, range; 5.18-8.34 kg/m2) (p<0.001) compared with the baseline value (6.61, range; 5.65-9.24 kg/m2), but recovered to baseline value at three months (6.51, range; 5.65-8.73) (p=0.115), six months (6.64, range; 5.23-8.73) (p=0.093), 12 months (6.65, range; 5.65-8.68) (p=0.062). There was no change in the sarcopenia rate at any point.